PEPDIA-PLP-001707

the 5 μg/ml concentration exhibited the strongest inhibitory effect with only 1.8% RNV area (Figure 1A, C, and D).

the 2.5 μg/ml group showed 5.8% RNV area (Figure 1A, C, and D).

the 1.25 μg/ml group demonstrated 6.28% RNV area (Figure 1A, C, and D).

wound healing assays demonstrated that LCKLSL significantly suppressed hypoxia-induced endothelial cell migration capacity (Figure 5)

tube formation assays showed significant suppression of capillary-like network complexity (Figure 6)

transwell invasion assays showed reduction in cellular invasiveness (Figure 6)

Maximal HUVEC metabolic activity was observed under 24-h hypoxic induction, with subsequent dose-response analysis identifying 10 μM LCKLSL as the optimal concentration for significant anti-proliferative effects (Figure 4A and B).

TUNEL assays revealed comparable apoptotic rates between LCKLSL-treated and control group (p>0.05) (Figure 4C and D), confirming the non-cytotoxic profile of LCKLSL within the experimental dose range.

Quantitative analysis demonstrated equivalent retinal thickness measurements between treatment and control groups (p>0.05) (Figure 2C).

ERG recordings... revealed transient reductions in a-wave and b-wave amplitudes on day 3 post-intervention. However, these functional changes showed no statistical significance (p>0.05) (Figure 2D, E, and F).

ERG recordings... revealed transient reductions in a-wave and b-wave amplitudes on day 3 post-intervention. However, these functional changes showed no statistical significance (p>0.05) (Figure 2D, E, and F).

Systemic safety assessment confirmed... no significant abnormalities in body weight in LCKLSL peptide-administered mice (Figure 3).

Figure 5D: The decreased Annexin A2-immunoprecipitated HSP90 and the decreased HSP90-immunoprecipitated Annexin A2 under the treatments of ... 10 µM hexapeptide LCKLSL (HEXA).

Figure 5I: All of them [matrine, PY60, and hexapeptide] increased the HSP90-immunoprecipitated TAP1 contents.

Figure 5K: The LDH release experiment showed that the treatments of matrine, PY60, and hexapeptide enhanced the killing of human CD8+ T cells on human Huh7 cells.

10 μM LCKLSL treatment significantly suppressed surface tPA binding in HRMECs under stimulation of hypoxia (1% O2) and VEGF (20 ng/ml) (Figure 9B)